Capricorn Fund Managers acquired a new stake in Ionis Pharmaceuticals in Q3 2025, holding 162,800 shares valued at $10.65 million post-trade. This represents 3.58% of the fund’s AUM, placing it outside the top five holdings. Ionis Pharmaceuticals saw a surge in stock price, up 86.6% over the past year.

On October 17, 2025, Capricorn Fund Managers disclosed a new position in Ionis Pharmaceuticals, acquiring 162,800 shares valued at $10.65 million. This stake represents 3.58% of the fund’s AUM and is a new addition to their portfolio. Ionis Pharmaceuticals’ stock price has been on the rise, outperforming the S&P 500.

Ionis Pharmaceuticals develops RNA-targeted therapeutics with products like SPINRAZA and TEGSEDI. The company has seen significant growth in recent months, with its stock price increasing by over 72%. While the outlook is positive with new products and FDA approvals, regulatory challenges and concerns of overvaluation remain. Investors are closely monitoring the company’s performance.

Read more at NASDAQ: Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares